Clinical trials: Superficial Vein Thrombosis
Thrombosis, Venous
ARIXTRA® Adherence in SVT Patients.
Fondaparinux is an anticoagulant used in the prevention and treatment of thromboembolic disease. It has recently been approved in the European Union (EU) for the treatment of patients with isolated superficial vein thrombosis…
- Trial name
- NCT01691495
- Testing
- Fondaparinux
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Chronic Venous Thrombosis, Venous Thrombosis Upper Extremity
Surfacer System to Facilitate Access in Venous Occlusions
Prospective, single-arm, multicentre, international Registry of the Surfacer System for the treatment of patients with limited or diminishing upper body venous access or pathology impeding standard access methods.The purpose of…
- Conditions
- Chronic Venous Thrombosis, Venous Thrombosis Upper Extremity, Venous Thrombosis Upper Extremity Superficial Veins
- Trial name
- SAVE (NCT02875899)
- Where
- 4 sites in Austria, Germany and 1 more
- Volunteers
- 30 people
- Sponsor
- Merit Medical Systems, Inc.
Thrombophlebitis, Phlebitis
Efficacy and Tolerability of Hirudoid Cream in Prophylaxis and Treatment Infusion Phlebitis
Patients receiving nutritional emulsion for at least 3 days will be treated with Hirudoid cream or placebo cream to prevent and treat phlebitis caused by the infusion.
- Trial name
- NCT01943006
- Testing
- Hirudoid cream 0.3 % Mucopolysaccharide polysulfate
- Where
- 4 sites in Thailand
- Volunteers
- 144 people
- Sponsor
- Medinova AG
Thrombosis, Venous
Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)
To evaluate fondaparinux 2.5mg subcutaneously once daily for 45 days in the treatment of acute (recent) superficial thrombophlebitis.
- Trial name
- NCT00443053
- Where
- 227 sites in Bulgaria, Czechia and 15 more
- Volunteers
- 3,002 people
- Sponsor
- GlaxoSmithKline